Trinity Biotech PLC reports results for the quarter ended in December - Earnings Summary

Trinity Biotech

11/04/2022 23:31

* Trinity Biotech PLC  TRIB.OQ  reported a quarterly
adjusted loss
of 6 cents​​ per share for the quarter ended in December. The
lone analyst forecast for the quarter was for earnings of 7
cents per share.
    * Revenue fell 40.4% to $19.53 million from a year ago; 
analysts
expected $24.00 million. 
    * Trinity Biotech PLC's reported EPS for the quarter was a
loss
of 6 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Trinity Biotech PLC shares had fallen by 7.5% this
quarter and
lost 31.4% so far this year.
    * Wall Street's median 12-month price target for Trinity
Biotech
PLC is $4.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated April 11 at 10:31 p.m.  ​All
figures in US dollars unless otherwise stated